Kia Z. Perez-Vale

Kia Z. Perez-Vale

Auto-generated profile, based on publicly available information

Kia Z. Perez-Vale

Janssen Research and Development, Spring House, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies. Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247

11 November 2021 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
KPKia Z. Perez-Vale
Kia Z. Perez-Vale
KYKristi D. Yow
Kristi D. Yow
RJRuth I. Johnson
Ruth I. Johnson
ABAmy E. Byrnes
Amy E. Byrnes
TFTara Finegan
Tara Finegan
MPMark Peifer
Mark Peifer
Embryogenesis requires cells to change shape and move without disrupting epithelial integrity. This requires robust, responsive linkage between adherens junctions and the actomyosin cytoskeleton. Using Drosophila morphogenesis, we define molecular mechanisms mediating junction–cytoskeletal linkage and explore the role of mechanosensing. We focus on the junction–cytoskeletal linker Canoe, a multidomain protein. We engineered the canoe locus to define how its domains mediate its mechanism of action. To our surprise, the PDZ and FAB domains, which we thought connected junctions and F-actin, are not required for viability or mechanosensitive recruitment to junctions under tension. The FAB domain stabilizes junctions experiencing elevated force, but in its absence, most cells recover, suggesting redundant interactions. In contrast, the Rap1-binding RA domains are critical for all Cno functions and enrichment at junctions under tension. This supports a model in which junctional robustness derives from a large protein network assembled via multivalent interactions, with proteins at network nodes and some node connections more critical than others.

6 September 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
RRRicardo Rivera-Soto
Ricardo Rivera-Soto
BHBenjamin Henley
Benjamin Henley
MPMarian A. Pulgar
Marian A. Pulgar
SLStacey Lehman
Stacey Lehman
HGHimanshu Gupta
Himanshu Gupta
SMSheri L. Moores
Sheri L. Moores
Amivantamab is an FDA-approved bispecific antibody targeting EGF and Met receptors, with clinical activity against EGFR mutant non-small cell lung cancer (NSCLC). Amivantamab efficacy has been demonstrated to be linked to three mechanisms of action (MOA): immune cell-mediated killing, receptor internalization and degradation, and inhibition of ligand binding to both EGFR and Met receptors. Among the EGFR ligands, we demonstrated that amphiregulin (AREG) is highly expressed in wild-type (WT) EGFR (EGFRWT) NSCLC primary tumors, with significantly higher circulating protein levels in NSCLC patients than in healthy volunteers. Treatment of AREG-stimulated EGFRWT cells/tumors with amivantamab or with an AREG-targeting antibody inhibited ligand-induced signaling and cell/tumor proliferation/growth. Across 11 EGFRWT NSCLC patient-derived xenograft models, amivantamab efficacy correlated with AREG RNA levels. Interestingly, in these models, amivantamab anti-tumor activity was independent of Fc engagement with immune cells, suggesting that, in this context, the ligand-blocking function is sufficient for amivantamab maximal efficacy. Finally, we demonstrated that in lung adenocarcinoma patients, high expression of AREG and EGFR mutations were mutually exclusive. In conclusion, these data 1) highlight EGFR ligand AREG as a driver of tumor growth in some EGFRWT NSCLC models, 2) illustrate the preclinical efficacy of amivantamab in ligand-driven EGFRWT NSCLC, and 3) identify AREG as a potential predictive biomarker for amivantamab activity in EGFRWT NSCLC.

4 April 2023
Verified
Other
Open access
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
MRTX1133 reduces metastatic burden in a tail vein model

4 April 2023
Verified
Other
Open access
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies.Significance:Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC.See related commentary by Redding and Grabocka, p. 260.This article is highlighted in the In This Issue feature, p. 247

4 April 2023
Verified
Other
Open access
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
KRASG12D inhibition alters the tumor immune microenvironment